Search Results

1 - 10 of 222 items :

  • "doxorubicin" x
Clear All

REFERENCES 1. Olson RD, Mushlin PS, Brenner DE, Fleischer S, Cusack BJ, Chang BK, Boucek RJ: Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A 1988, 85:3585-3589. 2. Warpe VS, Mali VR, Arulmozhi S, Bodhankar SL, Mahadik KR: Cardioprotective effect of ellagic acid on doxorubicin induced cardiotoxicity in wistar rats. J Acute Med 2015, 5:1-8. 3. Gorini S, De Angelis A, Berrino L, Malara N, Rosano G, Ferraro E: Chemotherapeutic drugs and mitochondrial dysfunction: Focus on doxorubicin, trastuzumab, and sunitinib

References 1. Adams J.: Development of the Proteasome Inhibitor PS-341. The Oncologist, 7, 9, 2002. 2. Aihara Y. et al.: Doxorubicin Represses CARP Gene Transcription Through the Generation of Oxidative Stress in Neonatal Rat Cardiac Myocytes: Possible Role of Serine/Threonine Kinase - dependent Pathways. J. Mol. Cell Cardiol., 32, 1401, 2000. 3. Batheja R. et al.: Paradoxical decrease in plasma N-terminal-proBNP (NTproBNP) levels in patients receiving doxorubicin chemotherapy and declining left ventricular ejection fraction. J. Am. Coll. Cardiol., 47, 66A, 2006

References 1. Andryskowski G., Owczarek T.: Ocena wybranych parametrow stresu oksydacyjnego u chorych z nadczynnością tarczycy Pol. Arch. Med. Wewn., 117, 285, 2007. 2. Berthiaume JM, Wallace KB.: Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment. Cardiovascular Toxicol., 7, 178, 2007. 3. Carvalho R.A., at al.: Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology., 270, 92, 2010. 4. Dudka J, et al.: Activity of NADPH-cytochrome P-450 reductase of the human heart, liver

REFERENCES 1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229. 2. Praet M, Pollakis G, Goormaghtigh E, Ruysschaert JM. Damages of the mitochondrial membrane in Adriamycin treated mice. Cancer Lett. 1984;25:89-96. 3. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 2001;61:771-7. 4. Arai M, Tomaru K, Takizawa T, Sekguchi

REFERENCES 1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev . 2004; 56:185-229. 2. Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev . 2014;34: 106-35. 3. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol . 2005;23:7685-96. 4. Sardao, VA, Oliveira

, Klingebiel T, Cinatl J Jr (2003) Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer   104 : 36-43. Lesca P, Beaune P, Monsarrat B (1981) Ellipticines and human liver microsomes: spectral interaction with cytochrome P-450 and hydroxylation. Inhibition of arylhydrocarbon metabolism and mutagenicity. Chem-Biol Interact   36 : 299-309. Maris JM, Mathay KK (1999) Molecular biology of neuroblastomas. J Clin Oncol   17 : 2264-2279. Murray GI, Weaver RJ

REFERENCES 1. Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcade™) in the treatment of multiple myeloma, Ther and Clin Risk Manag . 2006; 2:271-9. 2. Romaniuk W, Ołdziej AE, Zińczuk J, Kłoczko J. Proteasome inhibitors in cancer therapy. Postepy Hig Med Dosw. 2015;69: 1443-50. 3. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem . 2009;16:3267-85. 4. Lipchick BC, Fink EE, Nikiforov MA. Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol

. Kalender, Y. Kalender, A. Ates, M. Yel, E. Olcay and S. Candan, Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats, Braz. J. Med. Biol. Res. 35 (2002) 1379-1387; DOI: 10.1590/s0100-879x2002001100017. 5. Y. Kalender, M. Yel and S. Kalender, Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats - the effects of vitamin E and catechin, Toxicology 209 (2005) 39-45; DOI: 10.1016/j.tox.2004.12.003. 6. J. H. Doroshow, Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical

References 1. A. M. Stuckey, Breast cancer: epidemiology and risk factors, Clin. Obst. Gynecol. 54 (2011) 96-102; DOI: 10.1097/GRF.0b013e3182080056. 2. F. C. Thorn, C. Oshiro, S. Marsh, T. Hernandez-Boussard, H. McLeod, T. Klein and B. R. Altman, Doxorubicin pathways: pharmacodynamics and adverse effects, Pharmacogenet. Genom. 21 (2011) 440-446; DOI: 10.1097/FPC.0b013e32833ffb56. 3. A. Jashari, F. Imeri, L. Ballazhi, A. Shabani, B. Mikhova, G. Dräger, E. Popovski and A. Huwiler, Synthesis and cellular characterization of novel isoxazolo- and

with intermediate-stage HCC, but due to heterogeneity of the patient population in this stage, tumor response and survival rates are variable and scattered across the literature. 2 - 4 Several clinical studies have confirmed the benefits of doxorubicin-loaded DC Bead (DEBDOX; drug-eluting bead doxorubicin] with respect to improved tumor response, reduced adverse events and improved survival. 5 - 10 Furthermore, recent data shows that superselective TACE is associated with lower adverse events, higher rate of tumor response and increased survival. 11 - 13 In